全文获取类型
收费全文 | 74581篇 |
免费 | 6021篇 |
国内免费 | 3273篇 |
专业分类
耳鼻咽喉 | 300篇 |
儿科学 | 1196篇 |
妇产科学 | 818篇 |
基础医学 | 11521篇 |
口腔科学 | 843篇 |
临床医学 | 5382篇 |
内科学 | 18126篇 |
皮肤病学 | 1073篇 |
神经病学 | 5347篇 |
特种医学 | 1269篇 |
外国民族医学 | 10篇 |
外科学 | 5484篇 |
综合类 | 8593篇 |
现状与发展 | 14篇 |
预防医学 | 3820篇 |
眼科学 | 1136篇 |
药学 | 10991篇 |
11篇 | |
中国医学 | 2367篇 |
肿瘤学 | 5574篇 |
出版年
2023年 | 839篇 |
2022年 | 1205篇 |
2021年 | 2101篇 |
2020年 | 2029篇 |
2019年 | 2629篇 |
2018年 | 2625篇 |
2017年 | 2530篇 |
2016年 | 2603篇 |
2015年 | 2913篇 |
2014年 | 4703篇 |
2013年 | 5583篇 |
2012年 | 4357篇 |
2011年 | 4923篇 |
2010年 | 3841篇 |
2009年 | 3822篇 |
2008年 | 3851篇 |
2007年 | 3823篇 |
2006年 | 3427篇 |
2005年 | 2950篇 |
2004年 | 2597篇 |
2003年 | 2268篇 |
2002年 | 1908篇 |
2001年 | 1581篇 |
2000年 | 1382篇 |
1999年 | 1190篇 |
1998年 | 959篇 |
1997年 | 995篇 |
1996年 | 740篇 |
1995年 | 801篇 |
1994年 | 694篇 |
1993年 | 552篇 |
1992年 | 452篇 |
1991年 | 392篇 |
1990年 | 327篇 |
1989年 | 293篇 |
1988年 | 252篇 |
1987年 | 215篇 |
1985年 | 616篇 |
1984年 | 688篇 |
1983年 | 535篇 |
1982年 | 496篇 |
1981年 | 488篇 |
1980年 | 430篇 |
1979年 | 382篇 |
1978年 | 319篇 |
1977年 | 261篇 |
1976年 | 282篇 |
1975年 | 274篇 |
1974年 | 214篇 |
1973年 | 203篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
目的 探讨微小RNA-148a-3p(miR-148a-3p)对丝裂原活化蛋白激酶激酶激酶9(MAP3K9)的靶向调控作用及对胃癌细胞增殖和凋亡的影响。方法 向对数生长期胃癌细胞株MGC-803转染miR-148a-3p模拟物(mimics组)和阴性对照(NC组),以未转染的MGC-803细胞为对照组;采用实时定量PCR(QPCR)检测各组miR-148a-3p水平以评价转染效率,MTT法检测各组细胞增殖能力,流式细胞术检测各组细胞凋亡情况,分别采用QPCR和Western blotting检测Bcl-2、Bax、caspase-3及MAP3K9 mRNA和蛋白水平,同时采用双荧光素酶报告实验验证miR-148a-3p与MAP3K9的靶向作用关系。结果 QPCR结果显示,对照组、NC组和mimics组的miR-148a-3p水平分别为1.021±0.123、1.087±0.196和2.854±0.368,与对照组和NC组比较,mimics组的miR-148a-3p水平升高(P<0.05)。mimics组MGC-803细胞的增殖活力较其余两组减弱(P<0.05)。mimics组MGC-803细胞凋亡率为(15.2±1.6)%,高于对照组的(3.5±0.9%)%和NC组的(4.5±1.1)%,差异具有统计学意义(P<0.05)。与对照组和NC组比较,mimics组的MAP3K9和Bcl-2的mRNA和蛋白水平均下调,而Bax和caspase-3的mRNA和蛋白水平均上调(P<0.05);双荧光素酶报告实验证实MAP3K9是miR-148a-3p的直接作用靶点。结论 MiR-148a-3p可抑制胃癌细胞MGC-803的增殖并诱导其凋亡,可能通过靶向MAP3K9来发挥抑癌作用,调控miR-148a-3p/MAP3K9轴在胃癌防治中有一定应用前景。 相似文献
42.
43.
目的:以灰毡毛忍冬为材料,克隆对-香豆酸3-羟化酶(LmC3H1)基因,进行生物信息学和表达模式分析,结合绿原酸含量,研究推测灰毡毛忍冬LmC3H1基因的功能。方法:通过逆转录聚合酶链式反应(RT-PCR)和RACE技术克隆LmC3H1基因的全长c DNA序列,对该序列进行生物信息学分析,并利用实时荧光定量PCR(Real-time PCR)和HPLC分别测定灰毡毛忍冬茎、叶及不同花期花中LmC3H1的相对表达量及绿原酸含量。结果:克隆得LmC3H1(Gen Bank:MN177695)基因,开放阅读框(ORF)长度为1 533 bp,编码510个氨基酸,推测其分子式为C_(2618)H_(4134)N_(718)O_(727)S_(22),相对分子质量为58 005.32,等电点8.92,为亲水性蛋白,定位于叶绿体中,具有跨膜区域LLLIPAVLFLISLVYPLI,含有细胞色素P450的保守结构域CYTOCHROME_P450(422-433 aa);Real-time PCR结果显示,LmC3H1在灰毡毛忍冬茎、叶及不同花期花有不同程度的表达,其中在花发育阶段,白色花蕾期相对表达量最高,花蕾初期及白色开花期次之;白色花蕾期花与茎、叶比,花的相对表达量最高,叶的最低;HPLC结果显示,从绿白色花蕾期到金黄色开花期绿原酸含量呈上升趋势,金黄色开花期含量最高,不同器官中,花中绿原酸最高,茎最低。结论:克隆得到灰毡毛忍冬LmC3H1基因,推测LmC3H1可能参与灰毡毛忍冬花绿原酸的生物合成。该研究为进一步研究该基因的功能及探究灰毡毛忍冬绿原酸生物合成和调节机制提供了依据,同时为遗传改良灰毡毛忍冬品质奠定了基础。 相似文献
44.
The US Food and Drug Administration granted acalabrutinib approval as the second Bruton tyrosine kinase (BTK) inhibitor to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma as monotherapy or in combination with obinutuzumab. This approval was based on 2 phase 3 trials: ELEVATE-TN and ASCEND. There are several concerns with the design of these trials, including suboptimal treatment of patients in the control arm, expansion of the trial population, and lack of data regarding efficacy or tolerability compared with ibrutinib, a first-in-class drug. The Food and Drug Administration approval of acalabrutinib for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma represents concerning drug approval patterns in the United States and a weakness in evidence generation. 相似文献
45.
Alberto D’Angelo Navid Sobhani Stefan Bagby Andrea Casadei-Gardini Giandomenico Roviello 《Expert review of clinical pharmacology》2020,13(6):623-629
ABSTRACT
Introduction
Hepatocellular carcinoma (HCC) is one of the most frequent tumors affecting the gastrointestinal tract and a universal cause of morbidity and mortality. Cabozantinib is a strong multi-inhibitor of receptor tyrosine kinases approved for renal cell carcinoma that could be useful also for the treatment of HCC. 相似文献46.
Alicia M. Blessing MD PhD Janice M. Santiago-O'Farrill MD PhD Weiqun Mao BS MD Lan Pang BS MD Jing Ning MD PhD Daewoo Pak MD PhD Lakshmi Reddy Bollu MD PhD Philip Rask BS MD LaKesla Iles BS MD Hailing Yang PhD MD Samantha Tran BS MD Ezzeddine Elmir BS MD Geoffrey Bartholomeusz MD PhD Robert Langley MD PhD Zhen Lu MD Robert C. Bast Jr MD 《Cancer》2020,126(15):3579-3592
47.
Objective
This paper constitutes the first attempt to draw lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.Study Design
Taking the example of new direct-acting antivirals against hepatitis C virus, the paper asks whether and how the cost-effectiveness (CE) opinions issued by the French National Health Authority improve the information available to support the pricing decisions.Methods
The analysis compares the assessment of these drugs based on three different sources: CE opinions, clinical opinions, and the published cost-utility analyses (CUA) available in the literature and identified through a systematic review.Results
The results show that CE opinions bring to the fore three issues prone to impact the incremental cost utility ratio and those were not available to the decision maker through clinical opinions or published CUA: the stage of treatment initiation, the modeling of the disease progression, and the uncertainty around the efficacy rates.Conclusions
France has introduced the criterion of the cost per QALY gained in the pricing and regulation of innovative pharmaceuticals since 2013. Our analysis shows that the use of CUA does enhance the information available to the decision makers on the value of the treatments. 相似文献48.
Christopher L. Heidler Eva K. Roth Markus Thiemann Claudia Blattmann Ramon L. Perez Peter E. Huber Michal Kovac Beate Amthor Gabriele Neu-Yilik Andreas E. Kulozik 《International journal of cancer. Journal international du cancer》2020,147(4):1059-1070
Progress in the systemic control of osteosarcoma has been limited over the past decades thus indicating the urgent clinical need for the development of novel treatment strategies. Therefore, we have recently developed new preclinical models to study promising novel agents for the treatment of pediatric osteosarcoma. The checkpoint kinase (chk) inhibitor prexasertib (LY2606368) and its salt form (LSN2940930) have recently been shown to be active in adult and pediatric malignancies, including sarcoma. We have now tested the potency of prexasertib in clonogenic survival assays in two new lines of primary patient-derived osteosarcoma cells and in two established osteosarcoma cell lines as a single agent and in combination with cisplatin and the poly ADP-ribose polymerase (PARP) inhibitor talazoparib. Prexasertib alone results in strongly reduced clonogenic survival at low nanomolar concentrations and acts by affecting cell cycle progression, induction of apoptosis and induction of double-stranded DNA breakage at concentrations that are well below clinically tolerable and safe plasma concentrations. In combination with cisplatin and talazoparib, prexasertib acts in a synergistic fashion. Chk1 inhibition by prexasertib and its combination with the DNA damaging agent cisplatin and the PARP-inhibitor talazoparib thus emerges as a potential new treatment option for pediatric osteosarcoma which will now have to be tested in preclinical primary patient derived in vivo models and clinical studies. 相似文献
49.
50.
B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoting T cell response, and killing cancer cells directly. Given these properties, their anti-tumor immune response in the tumor micro-environment (TME) is of great interest. Although T cell-related immune responses have become a therapeutic target with the introduction of immune checkpoint inhibitors, not all patients benefit from these treatments. B cell and B cell-related pathways (CCL19, −21/CCR7 axis and CXCL13/CXCR5 axis) play key roles in activating immune response through humoral immunity and local immune activation via tertiary lymphoid structure (TLS) formation. However they have some protumorigenic works in the TME. Thus, a better understanding of B cell and B cell-related pathways is necessary to develop effective cancer control. In this review, we summarize recent evidences regarding the roles of B cell and B cell-related pathways in the TME and immune response and discuss their potential roles for novel cancer treatment strategies. 相似文献